Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14762115 | 0.99 | CRACR2A (0.49) | CRACR2ATSHRMEN1KMT2AHDAC1 | |
| SCHEMBL14761975 | 0.91 | UGCG (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL14762024 | 0.90 | KCNK3 (0.45) | NAMPT | |
| SCHEMBL14773843 | 0.89 | RAF1 (0.42) | — | |
| SCHEMBL14761897 | 0.88 | NAMPT (0.53) | CRACR2ATSHRMEN1KMT2ANAMPT | |
| SCHEMBL14762301 | 0.87 | NAMPT (0.55) | TSHRMEN1KMT2ANAMPTLMNA | |
| SCHEMBL14773836 | 0.85 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14773904 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL14761803 | 0.84 | SCN10A (0.44) | MEN1KMT2A | |
| SCHEMBL14762236 | 0.83 | SCN10A (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755950-B1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | claimed |
| CN-103796995-B | N- (5-cycloalkyl-or 5-heterocyclyl) -pyridin-3-ylcarboxamide | HOFFMAN-LA ROCHE LTD. (CH) | 2015-10-07 | — | — | CN | claimed |
| US-8455501-B2 | N-(5-cycloalkyl)-pyridin-3-yl carboxamides | Hoffmann-La Roche Inc (US) | 2013-06-04 | — | — | US | claimed |
| US-20130065911-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2013-03-14 | — | — | US | claimed |
| EP-2755950-B1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| EP-2755950-B1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| CN-103796995-B | N- (5-cycloalkyl-or 5-heterocyclyl) -pyridin-3-ylcarboxamide | HOFFMAN-LA ROCHE LTD. (CH) | 2015-10-07 | — | — | CN | disclosed |
| EP-2755950-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8455501-B2 | N-(5-cycloalkyl)-pyridin-3-yl carboxamides | Hoffmann-La Roche Inc (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455501-B2 | N-(5-cycloalkyl)-pyridin-3-yl carboxamides | Hoffmann-La Roche Inc (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2013037704-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037704-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065911-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130065911-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065911-A1 | N-(5-CYCLOALKYL- OR 5-HETEROCYCLYL-)-PYRIDIN-3-YL CARBOXAMIDES | APOB, PCSK9, CETP | CRACR2A 1844/4885TSHR 1883/4885MEN1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.